Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation.

08:00 EDT 1st June 2018 | BioPortfolio

Summary of "Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation."

T315I mutation is the most common BCR-ABL mutation and confers resistance to all the first and second generation BCR-ABL tyrosine kinases, including nilotinib and dasatinib. We report a high risk chronic myelogenous leukemia (CML) patient harboring the T315I mutation treated by Interferon-α (INF-α) solo and subsequently combined with dasatinib.


Journal Details

This article was published in the following journal.

Name: Clinical laboratory
ISSN: 1433-6510
Pages: 1061-1064


DeepDyve research library

PubMed Articles [59002 Associated PubMed Articles listed on BioPortfolio]

Chronic Myelogenous Leukemia.

The advent of tyrosine kinase inhibitors (TKI) has improved prognosis and outcome of patients with chronic myelogenous leukemia (CML) considerably. In comparison to imatinib, first line use of second ...

Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.

Hepatocellular carcinoma (HCC) is a major complication of chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Accumulating data suggest that antiviral treatment in both CHB and CHC reduces the in...

Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment.

Risk of depression and suicide in patients on interferon remains also after the treatment, the pathogenesis of which is still unclear. We aimed to determine the influence of the PEG-IFN-α2a on trypto...

Quantitative analysis of serum chemokines associated with treatment failure of direct-acting antivirals in chronic hepatitis C.

Although serum chemokine levels have been reported to influence the outcome of interferon-based treatment in patients with chronic hepatitis C, their effect on the hepatitis C virus (HCV) response to ...

Individualized Treatment of Chronic Lymphocytic Leukemia (CLL).

Because of the excellent prognosis in early asymptomatic stage of the disease all patients outside clinical trial should undergo "watch & wait" independently of their individual risk profile. Prognost...

Clinical Trials [23040 Associated Clinical Trials listed on BioPortfolio]

Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Low doses of interferon alfa may be as effective as high doses. PURPOSE: Randomized phase III trial to compare th...

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukem...

Polyethylene Glycol Interferon Alfa-2b Versus Interferon Alfa-2b in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026/MK-4031-001)

The primary purpose of this study is to compare the efficacy of pegylated interferon alfa-2b (PEG Intron, C98026) versus interferon alfa-2b (Intron® A) in the treatment of participants wi...

STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

RATIONALE: Biological therapies such as interferon-alfa and STI571 may interfere with the growth of cancer cells. It is not yet known if STI571 is more effective than interferon alfa plus ...

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys) or Recombinant Interferon Alfa-2a (Roferon-A) in Prior Clinical Studies

This open label extension study will give an opportunity to the participants that have responded to the treatment with Pegylated-Interferon Alfa-2a (PEG-INF) or Roferon-A in prior clinical...

Medical and Biotech [MESH] Definitions

A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS.

Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).

Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.

An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).

An interferon regulatory factor that binds upstream TRANSCRIPTIONAL REGULATORY ELEMENTS in the GENES for INTERFERON-ALPHA and INTERFERON-BETA. It functions as a transcriptional activator for the INTERFERON TYPE I genes.

Quick Search

DeepDyve research library

Searches Linking to this Article